Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — FY2024 Earnings Presentation
14 slides from Day One Biopharmaceuticals's earnings presentation, Feb 25, 2025
Slide 1: Fourth Quarter & Full-Year 2024 Financial Results & Corporate Progress
Day One Biopharmaceuticals FEBRUARY 2025 Fourth Quarter & Full-Year 2024 Financial Results & Corporate Progress
Slide 2: Forward looking statements
Forward looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc
Slide 3: Agenda & Day One participants
Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM (tovorafenib) Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating Officer & Chief Financial Officer) Q&A Session All, joined by: Elly Barry (Chief Medical Officer) Agenda & Day One participan
Slide 4: Opening Remarks
Jeremy Bender Chief Executive Officer Opening Remarks
Slide 5: Fourth quarter and full year 2024 highlights
1 Represents cash, cash equivalents and short-term investments as of December 31, 2024. Fourth quarter and full year 2024 highlights OJEMDA $29.0M in net product revenues in Q4 2024, $57.2M in 2024 Delivered strong revenue as the foundation of our growing business Pipeline Progress FIREFLY-2 trial e
Slide 6: OJEMDA Launch Performance
Lauren Merendino Chief Commercial Officer OJEMDA Launch Performance
Slide 7: Commercial performance in launch year
Commercial performance in launch year 1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2 Prescriptions are approximations based on data available as of December 31, 2024. $57.2M 2024 OJEMDA Net Product Revenue ~88%
Slide 8: OJEMDA Revenue Strong Uptake Continues
1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2 In December 2024, the Centers for Medicare & Medicaid Services (CMS) agreed that OJEMDA is approved exclusively for pediatric indications, reducing its Medicaid and
Slide 9: Depth of Prescribing by Account Since Launch
1 Analysis includes on-label, non-EAP patients only and data are approximations based on SP reporting as of December 31, 2024. 100% Goal Breadth of Accounts Treating ≥ 1 Patient on OJEMDA1 (N = 17) (N = 85) (N = 110) Launch Dec 2024 1 Patient 2 Patients 3+ Patients OJEMDA U.S. prescriptions continue
Slide 10: Coverage approval rates remain high across both Commercial and Medicaid payers
1 Breakaway Partners LLC – Breakaway Partners Analytics Platform. Metrics Based on 190.5M Commercial Lives . 2 Artia Solutions - Medicaid Coverage Status Report and Breakaway Partners LLC – Breakaway Partners Analytics Platform. Metrics Based on 73.9M Total Medicaid Lives. 3 Includes on-label patien
Slide 11: OJEMDA priorities to drive revenue growth in 2025
Continue to increase breadth and depth of prescribers Establish OJEMDA as standard of care in 2nd line relapsed or refractory BRAF-altered pLGG Support prescribers and patients to allow for optimal duration of treatment OJEMDA priorities to drive revenue growth in 2025
Slide 12: Financial Performance
Charles York Chief Operating Officer & Chief Financial Officer Financial Performance
Slide 13: Financial Summary
All financial information is unaudited. 1 Includes stock-based compensation expense of $3.5 million and $16.7 million for the three and twelve months ended 12/31/24, and $4.3 million and $14.4 million for the three and twelve months ended 12/31/23, respectively. 2 Includes stock-based compensation e
Slide 14: Thank you
Thank you
Day One Biopharmaceuticals — FY2024 Earnings Presentation on 6ix